共 50 条
Body mass index and phenotype in subjects with mild-to-moderate persistent asthma
被引:108
|作者:
Sutherland, E. Rand
[1
,2
]
Lehman, Erik B.
[3
]
Teodorescu, Mihaela
[4
]
Wechsler, Michael E.
[5
,6
]
机构:
[1] Natl Jewish Hlth, Denver, CO 80206 USA
[2] Univ Colorado, Denver, CO 80202 USA
[3] Penn State Univ, Dept Hlth Evaluat Sci, Hershey, PA USA
[4] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Sleep Inst, Sect Allergy Pulm & Crit Care Med,Dept Med, Madison, WI 53706 USA
[5] Brigham & Womens Hosp, Boston, MA 02115 USA
[6] Harvard Univ, Sch Med, Boston, MA USA
基金:
美国国家卫生研究院;
关键词:
Asthma;
obesity;
treatment;
severity;
RANDOMIZED CONTROLLED TRIAL;
CLINICAL-RESEARCH NETWORK;
OBSTRUCTIVE SLEEP-APNEA;
INHALED CORTICOSTEROIDS;
PULMONARY-FUNCTION;
NOCTURNAL ASTHMA;
OBESITY;
WOMEN;
EPIDEMIOLOGY;
ASSOCIATION;
D O I:
10.1016/j.jaci.2009.04.005
中图分类号:
R392 [医学免疫学];
学科分类号:
100102 ;
摘要:
Background: Although obesity has been hypothesized to worsen asthma, data from studies of subjects with well-characterized asthma are lacking. Objective: We sought to evaluate the relationship between body mass index (BMI), asthma impairment, and response to therapy. Methods: BMI (in kilograms per meter squared) and asthma phenotypic and treatment response data were extracted from Asthma Clinical Research Network studies. The cross-sectional relationship between BMI and asthma impairment was analyzed, as was the longitudinal relationship between BMI and response to asthma controller therapies. Results: One thousand two hundred sixty-five subjects with mild-to-moderate persistent asthma were evaluated. Analyses of lean versus overweight/obese asthmatic subjects demonstrated small differences in FEV(1) (3.05 vs 2.91 L, P = .001), FEV(1)/forced vital capacity ratio (mean, 83.5% vs 82.4%; P = .01), rescue albuterol use (1.1 vs 1.2 puffs per day, P = .03), and asthma-related quality of life (5.77 vs 5.59, P = .0004). Overweight/obese asthmatic subjects demonstrated a smaller improvement in exhaled nitric oxide levels with inhaled corticosteroid (ICS) treatment than did lean asthmatic subjects (3.6 vs 6.5 ppb, P = .04). With ICS/long-acting beta-agonist treatment, overweight/obese asthmatic subjects demonstrated smaller improvements in lung function than lean asthmatic subjects, with an 80 mL (P = .04) and 1.7% (P = .02) lesser improvement in FEV(1) and FEV(1)/forced vital capacity ratio, respectively. Significant differences in therapeutic response to leukotriene modifiers between BMI categories were not observed. Conclusions: Increased BMI is not associated with clinically significant worsening of impairment in subjects with mild-to-moderate persistent asthma. There is a modest association between increased BMI and reduced therapeutic effect of ICS-containing regimens in this patient population. Prospective studies evaluating the effect of being overweight or obese on treatment response in asthma are warranted. (J Allergy Clin Immunol 2009;123:1328-34.)
引用
收藏
页码:1328 / 1334
页数:7
相关论文